Chronic depression / Persistent Depressive Disorder (DSM-5) Mental and Behavioural Disorders
Conditions
Interventions
In our study, two approaches are to be combined in an approximately four-month treatment program: a metta-based group meditation program (MGM) focusing on the meditation of mindfulness and Metta/Lovin
and an individualized program for CBT (8 sessions, 50 min.), which is linked to the objectives of MGM.
Patients allocated for trial are randomly distributed uniformly to two test cond
German adaptation: Stangier & Mendes, 2015) and aims to focus on the perception of positive attitudes and feelings towards oneself and other persons. They consist of formulas in which wishes are formu
Sponsors
Goethe University.Frankfurt
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Primary DSM-5 diagnosis of persistent depressive disorder (PDD) confirmed by the SCID depression section 2. On/off medication stable for at least 4 weeks before inclusion 3. Age between 18 and 70 years 4. Informed consent
Exclusion criteria
Exclusion criteria: 1. Substance use disorders (current or within last 3 months) 2. Acute suicidality 3. Acute/past manic or psychotic symptoms 4. Borderline personality disorder 5. Organic mental disorder 6. Severe medical conditions 7. Concurrent psychotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of depressive symptoms, assessed by the Quick Inventory of Depressive Symptomatology, Clinical Rating (QIDS-C) and the Beck depression inventory-II (BDI-II) at baseline (T0), 8 weeks after baseline (after end of group treatment; T1), at the end of the entire treatment at 16 weeks after baseline (T2), and at 42 weeks after baseline (i.e. 6 months after end of overall treatment; T3) | — |
Secondary
| Measure | Time frame |
|---|---|
| All outcomes measured at baseline (T0) and at the end of the entire treatment, 16 weeks after baseline (T2). Furthermore, mindfulness, benevolence, rumination, emotion regulation (here only assessed by the ASQ), and behavioral and cognitive avoidance will also be measured at 8 weeks after baseline (after end of group treatment; T1) and at 42 weeks after baseline (i.e. 6 months after end of overall treatment; T3). Social motivation will also be measured at T3. 1. Mindfulness, assessed using the Five Facet Mindfulness Questionnaire (FFMQ) 2. Benevolence, assessed using the Compassionate Love Scale (CLS) 3. Rumination, assessed using the Response Styles Questionnaire, German version (RSQ-D) 4. Emotion regulation, assessed using the Affective Style Questionnaire (ASQ) and the Operationalized Skills Assessment Inventory 5. Social connectedness, assessed using the Inclusion of Other in the Self Scale (IOS) 6. Social motivation, assessed using the Social Adaptation Self-evaluation Scale (SASS) 7. Social pain, assessed using the Social Pain Questionnaire 8. Behavioral and cognitive avoidance, assessed using the Behavioral Activation for Depression Scale (BADS) | — |
Countries
Germany
Outcome results
None listed